We are live on ! Find out more
OBIO icon

Orchestra BioMed
OBIO

62 hedge funds and large institutions have $140M invested in Orchestra BioMed in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 16 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

220% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 5

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

5% more funds holding

Funds holding: 59 → 62 (+3)

1.05% more ownership

Funds ownership: 68.8% → 69.84% (+1%)

2% more capital invested

Capital invested by funds: $138M → $140M (+$2.31M)

Holders
62
Holders Change
+3
Holders Change %
+5.08%
% of All Funds
1.04%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
9
Increased
16
Reduced
5
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$2.74M
2
Millennium Management
Millennium Management
New York
+$1.94M
3
WRBC
W.R. Berkley Corp
Connecticut
+$1.82M
4
KPF
K2 Principal Fund
Ontario, Canada
+$1.74M
5
LSC
Logan Stone Capital
Illinois
+$1.64M

Top Sellers

Rank Fund Capital Flow
1
DKCM
Davidson Kempner Capital Management
New York
-$4.97M
2
PA
Perceptive Advisors
New York
-$4.46M
3
AAA
Affinity Asset Advisors
New York
-$2.97M
4
SCM
Shaolin Capital Management
Florida
-$1.98M
5
M
Murchinson
Ontario, Canada
-$992K
Name Holding Trade Value Shares
Change 		Change in
Stake
DFCM
51
Dark Forest Capital Management
Puerto Rico
$176K +$2.98K +300 +2%
Geode Capital Management
52
Geode Capital Management
Massachusetts
$123K – – –
6CM
53
683 Capital Management
New York
$100K – – –
ACM
54
Altium Capital Management
New York
$100K – – –
RCM
55
Rivernorth Capital Management
Florida
$100K – – –
TRCT
56
Tower Research Capital (TRC)
New York
$11K +$537 +54 +5%
Morgan Stanley
57
Morgan Stanley
New York
$7K – – –
UBS Group
58
UBS Group
Switzerland
$5K +$4.37K +440 +772%
CCM
59
Context Capital Management
California
$3K – – –
Northwestern Mutual Wealth Management
60
Northwestern Mutual Wealth Management
Wisconsin
$2K +$1.53K +154 New
Bank of Montreal
61
Bank of Montreal
Ontario, Canada
$1.99K – – –
MF
62
Magnetar Financial
Illinois
$414 +$2.56K +258 +0.6%
PA
63
Perceptive Advisors
New York
– -$4.46M -450,000 Closed
AAA
64
Affinity Asset Advisors
New York
– -$2.97M -300,000 Closed
SCM
65
Shaolin Capital Management
Florida
– -$1.98M -200,000 Closed
M
66
Murchinson
Ontario, Canada
– -$992K -100,115 Closed
SCC
67
Spring Creek Capital
Kansas
– -$460K -46,394 Closed
1 2
3

OBIO Hedge Fund Activity: Q2 2022 in Review

62 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q2 2022, worth a combined $140M — up 1.7% from $138M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new OBIO positions and 5 closed out — a net gain of 4 holders — while 16 added to existing stakes and 5 trimmed.

The largest buyer was Hudson Bay Capital Management, opening a new position worth an estimated $2.74M. The largest seller was Davidson Kempner Capital Management, cutting an estimated $4.97M.

  • 62 institutional investors held Orchestra BioMed (OBIO) as of Q2 2022, up from 59 in Q1 2022.
  • Funds reported $140M of Orchestra BioMed stock for Q2 2022, up 1.7% quarter-over-quarter.
  • 9 funds opened new Orchestra BioMed positions in Q2 2022 and 5 closed out, a net change of +4 holders.
  • The largest Orchestra BioMed buyer in Q2 2022 was Hudson Bay Capital Management, an estimated $2.74M added.
  • The largest Orchestra BioMed seller in Q2 2022 was Davidson Kempner Capital Management, an estimated $4.97M sold.

Based on aggregated 13F filings for Q2 2022.